# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis downgrades Astria Therapeutics (NASDAQ:ATXS) from Buy to Neutral.
Wedbush analyst Laura Chico downgrades Astria Therapeutics (NASDAQ:ATXS) from Outperform to Neutral and lowers the price tar...
JMP Securities analyst Jonathan Wolleben downgrades Astria Therapeutics (NASDAQ:ATXS) from Market Outperform to Market Perform.
Jefferies analyst Eun Yang downgrades Astria Therapeutics (NASDAQ:ATXS) from Buy to Hold and lowers the price target from $3...
BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...